Literature DB >> 11376229

Using drug claims data to assess the relationship of medication adherence with hospitalization and costs.

B L Svarstad1, T I Shireman, J K Sweeney.   

Abstract

OBJECTIVE: This naturalistic study used claims data to examine the relationship of medication nonadherence to hospital use and costs among severely mentally ill clients in Wisconsin.
METHODS: Data for 619 clients were obtained from Medicaid drug and hospital claims, county records, and case managers as part of a larger study in eight county-based mental health systems. Study participants were eligible for Medicaid, had a severe and persistent mental illness, were 18 years or older, and were receiving neuroleptics, lithium, or antidepressants. Drug claims were analyzed for a 12-month period to determine how regularly clients obtained their medications. Regression analyses were used to assess the effects of irregular medication use on any hospitalization for psychiatric problems, the number of days hospitalized, and hospital costs. The analyses controlled for several risk factors.
RESULTS: Among clients with schizophrenia or schizoaffective disorder, 31 percent used medications irregularly. The rates were 33 percent among those with bipolar disorder and 41 percent among those with other severe mental illnesses. In the total sample, irregular users had significantly higher rates of hospitalization than regular users (42 percent versus 20 percent), more hospital days (16 days versus four days), and higher hospital costs ($3,992 versus $1,048). Irregular medication use was one of the strongest predictors of hospital use and costs even after the analyses controlled for diagnosis, demographic characteristics, baseline functioning, and previous hospitalizations.
CONCLUSIONS: The availability of drug claims data and the ability to use them in predictive analyses make them a potentially useful data source in studies of medication adherence among persons with severe mental illness.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11376229     DOI: 10.1176/appi.ps.52.6.805

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  91 in total

1.  How patient cost-sharing trends affect adherence and outcomes: a literature review.

Authors:  Michael T Eaddy; Christopher L Cook; Ken O'Day; Steven P Burch; C Ron Cantrell
Journal:  P T       Date:  2012-01

2.  Association between sitagliptin adherence and self-monitoring of blood glucose.

Authors:  Somesh Nigam; Naunihal S Virdi; Mehmet Daskiran; Chris M Kozma; Andrew Paris; William M Dickson
Journal:  J Diabetes Sci Technol       Date:  2012-05-01

Review 3.  Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review.

Authors:  Jennifer B Levin; Anna Krivenko; Molly Howland; Rebecca Schlachet; Martha Sajatovic
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

4.  Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits.

Authors:  Kayla L Metzger; Jody M Shoemaker; Jonathan B Kahn; Christina R Maxwell; Yuling Liang; Jan Tokarczyk; Stephen J Kanes; Meredith Hans; Anthony M Lowman; Nily Dan; Karen I Winey; Neal R Swerdlow; Steven J Siegel
Journal:  Psychopharmacology (Berl)       Date:  2006-11-21       Impact factor: 4.530

5.  Development of controlled-release matrix tablet of risperidone: influence of Methocel®- and Ethocel®-based novel polymeric blend on in vitro drug release and bioavailability.

Authors:  Amir Badshah; Fazal Subhan; Khalid Rauf; Nadeem Irfan Bukhari; Kifayatullah Shah; Samiullah Khan; Zia Ahmed; Ihsanullah Khan
Journal:  AAPS PharmSciTech       Date:  2011-04-15       Impact factor: 3.246

6.  Use of depot antipsychotic medications for medication nonadherence in schizophrenia.

Authors:  Joyce C West; Steven C Marcus; Joshua Wilk; Lisa M Countis; Darrel A Regier; Mark Olfson
Journal:  Schizophr Bull       Date:  2007-12-18       Impact factor: 9.306

7.  Does Non-Adherence Increase Treatment Costs in Schizophrenia?

Authors:  Mark Pennington; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

8.  Identifying clinical net benefit of psychotropic medication use with latent variable techniques: Evidence from Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Authors:  Natalie Bareis; Juan Lu; Cynthia K Kirkwood; Susan G Kornstein; Elwin Wu; Briana Mezuk
Journal:  J Affect Disord       Date:  2018-05-29       Impact factor: 4.839

9.  Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.

Authors:  Natalie C Edwards; Julie C Locklear; Marcia F T Rupnow; Ronald J Diamond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

10.  Adherence to antipsychotics among Latinos and Asians with schizophrenia and limited English proficiency.

Authors:  Todd P Gilmer; Victoria D Ojeda; Concepcion Barrio; Dahlia Fuentes; Piedad Garcia; Nicole M Lanouette; Kelly C Lee
Journal:  Psychiatr Serv       Date:  2009-02       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.